Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 6
Submit an article Journal homepage
485
Views
11
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia

Jie JinDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Jian ChenDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Shanshan SuoDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Wenbin QianDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Haitao MengDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Wenyuan MaiDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Hongyan TongDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Jian HuangDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Wenjuan YuDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
,
Juyin WeiDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
&
Yinjun LouDepartment of Hematology, Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, ChinaCorrespondence[email protected]
 show all
Pages 1691-1697 | Received 03 Apr 2014, Accepted 01 Sep 2014, Published online: 03 Nov 2014

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Xiaorong Ma, Jin Wang, Yan Xu, Wanggang Zhang, Jie Liu, Xingmei Cao, Aili He, Fangxia Wang, Liufang Gu, Bo Lei & Jianli Wang. (2016) Dose-enhanced combined priming regimens for refractory acute myeloid leukemia and middle-and-high-risk myelodysplastic syndrome: a single-center, retrospective cohort study. OncoTargets and Therapy 9, pages 3661-3669.
Read now

Articles from other publishers (10)

Jun-Feng Zhu, Hai-Ping Dai, Qian-Qian Zhang, Jia Yin, Zheng Li, Qin-Ya Cui, Xiao-Peng Tian, Si-Ning Liu, Zheng-Ming Jin, Xia-Ming Zhu, De-Pei Wu & Xiao-Wen Tang. (2022) Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia. Frontiers in Oncology 12.
Crossref
Yan Pan, Yingjian Wang, Fangjian Chen & Zhiwei Liu. (2022) Association of Platelet Count Detected by Novel Nano Probe with Prognosis After Initial Chemotherapy in Patients with Acute Myeloid Leukemia. Journal of Biomedical Nanotechnology 18:10, pages 2433-2438.
Crossref
Chikashi Yoshida, Takeshi Kondo, Tomoki Ito, Masahiro Kizaki, Kazuhiko Yamamoto, Toshihiro Miyamoto, Yasuyoshi Morita, Tetsuya Eto, Yuna Katsuoka, Naoki Takezako, Nobuhiko Uoshima, Kazunori Imada, Jun Ando, Takuya Komeno, Akio Mori, Yuichi Ishikawa, Atsushi Satake, Junichi Watanabe, Yoshiko Kawakami, Tetsuo Morita, Ikue Taneike, Masahiko Nakayama, Yinghui Duan, Belen Garbayo Guijarro, Alexander Delgado, Cynthia Llamas & Hitoshi Kiyoi. (2022) Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. International Journal of Hematology 116:1, pages 89-101.
Crossref
Yan Huang, Minghua Hong, Zhigang Qu, Weiyan Zheng, Huixian Hu, Linjie Li, Ting Lu, Ying Xie, Shuangwei Ying, Yuanyuan Zhu, Lizhen Liu, Weijia Huang, Shan Fu, Jin Chen, Kangli Wu, Mingsuo Liu, Qiulian Luo, Yajun Wu, Fang He, Jingcheng Zhang, Junyu Zhang, Yu Chen, Minlei Zhao, Zhen Cai, He Huang & Jie Sun. (2021) Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients. Frontiers in Oncology 11.
Crossref
Arkadiusz Gajek, Aneta Rogalska & Aneta Koceva-Chyła. (2019) Aclarubicin in subtoxic doses reduces doxorubicin cytotoxicity in human non-small cell lung adenocarcinoma (A549) and human hepatocellular carcinoma (HepG2) cells by decreasing DNA damage. Toxicology in Vitro 55, pages 140-150.
Crossref
Jinqiu Chen, Nan Yang, Hailing Liu, Huan Yao, Jin Wang, Yun Yang & Wanggang Zhang. (2018) Immunological effects of a low‑dose cytarabine, aclarubicin and granulocyte‑colony stimulating factor priming regimen on a mouse leukemia model. Oncology Letters.
Crossref
Daisuke Minakata, Shin-ichiro Fujiwara, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi & Yoshinobu Kanda. (2017) Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. International Journal of Hematology 106:3, pages 411-417.
Crossref
Hui Liu, Rong Fu, Lijuan Li, Guojin Wang, Jia Song, Erbao Ruan, Huaquan Wang, Yuhong Wu, Xiaoming Wang, Kai Ding & Zonghong Shao. (2016) Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Clinical Drug Investigation 37:2, pages 167-174.
Crossref
Yi Chen, Ting Yang, Xiaoyun Zheng, Xiaozhu Yang, Zhihong Zheng, Jing Zheng, Tingbo Liu & Jianda Hu. (2016) The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy. Medicine 95:30, pages e4182.
Crossref
Daisuke Minakata, Shin-ichiro Fujiwara, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Yasufumi Kawasaki, Miyuki Sugimoto, Ryoko Yamasaki, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi & Yoshinobu Kanda. (2016) A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. Leukemia Research 42, pages 82-87.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.